Department of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
Department of Parasitology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
J Clin Lipidol. 2021 Nov-Dec;15(6):796-804. doi: 10.1016/j.jacl.2021.10.005. Epub 2021 Oct 31.
Besides the well-accepted role in lipid metabolism, high-density lipoprotein (HDL) also seems to participate in host immune response against infectious diseases.
We used a quantitative proteomic approach to test the hypothesis that alterations in HDL proteome associate with severity of Coronavirus disease 2019 (COVID-19).
Based on clinical criteria, subjects (n=41) diagnosed with COVID-19 were divided into two groups: a group of subjects presenting mild symptoms and a second group displaying severe symptoms and requiring hospitalization. Using a proteomic approach, we quantified the levels of 29 proteins in HDL particles derived from these subjects.
We showed that the levels of serum amyloid A 1 and 2 (SAA1 and SAA2, respectively), pulmonary surfactant-associated protein B (SFTPB), apolipoprotein F (APOF), and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) were increased by more than 50% in hospitalized patients, independently of sex, HDL-C or triglycerides when comparing with subjects presenting only mild symptoms. Altered HDL proteins were able to classify COVID-19 subjects according to the severity of the disease (error rate 4.9%). Moreover, apolipoprotein M (APOM) in HDL was inversely associated with odds of death due to COVID-19 complications (odds ratio [OR] per 1-SD increase in APOM was 0.27, with 95% confidence interval [CI] of 0.07 to 0.72, P=0.007).
Our results point to a profound inflammatory remodeling of HDL proteome tracking with severity of COVID-19 infection. They also raise the possibility that HDL particles could play an important role in infectious diseases.
除了在脂质代谢中发挥公认的作用外,高密度脂蛋白(HDL)似乎也参与了宿主对传染病的免疫反应。
我们采用定量蛋白质组学方法来检验以下假说,即 HDL 蛋白质组的变化与 2019 年冠状病毒病(COVID-19)的严重程度相关。
根据临床标准,将诊断为 COVID-19 的受试者(n=41)分为两组:一组为症状轻微的受试者,另一组为症状严重且需要住院的受试者。我们使用蛋白质组学方法,定量测定了来自这些受试者的 HDL 颗粒中的 29 种蛋白质的水平。
我们表明,血清淀粉样蛋白 A1 和 A2(分别为 SAA1 和 SAA2)、肺表面活性剂结合蛋白 B(SFTPB)、载脂蛋白 F(APOF)和α-胰蛋白酶抑制剂重链 H4(ITIH4)在住院患者中的水平分别增加了 50%以上,这与仅表现为轻度症状的受试者相比,其水平不受性别、HDL-C 或甘油三酯的影响。改变的 HDL 蛋白能够根据疾病的严重程度对 COVID-19 受试者进行分类(错误率为 4.9%)。此外,HDL 中的载脂蛋白 M(APOM)与 COVID-19 并发症导致的死亡几率呈负相关(APOM 每增加 1-SD,比值比为 0.27,95%置信区间为 0.07 至 0.72,P=0.007)。
我们的结果表明,HDL 蛋白质组在 COVID-19 感染的严重程度上发生了深刻的炎症重塑。它们还提出了 HDL 颗粒在传染病中可能发挥重要作用的可能性。